MINI REVIEW
Published on 28 Nov 2025
Overview of immune checkpoint inhibitor associated myocarditis mechanisms diagnostics and treatment
doi 10.3389/fimmu.2025.1677984
- 111 views
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Decoding the immunotherapy paradox: integrative approaches for balancing efficacy and immunotherapy-associated adverse events
Decoding the immunotherapy paradox: integrative approaches for balancing efficacy and immunotherapy-associated adverse events
3,457
Total downloads
17k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 17 Oct 2025
Analysis of the twelve cases of immune-related myocarditis caused by cadonilimab
doi 10.3389/fonc.2025.1671973
- 896 views
REVIEW
Published on 02 Sep 2025
Advances in the mechanisms, imaging characteristics and management strategies for immune checkpoint inhibitor-related pneumonitis
doi 10.3389/fimmu.2025.1656063
- 2,563 views
ORIGINAL RESEARCH
Published on 01 Sep 2025
Evaluating the toxicity profile of combination immune checkpoint inhibitors: a disproportionality analysis of real-world adverse events from the FDA Adverse Event Reporting System for tremelimumab, durvalumab, ipilimumab, and nivolumab
doi 10.3389/fimmu.2025.1631273
- 3,444 views
- 1 citation
CASE REPORT
Published on 22 Jul 2025
Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review
doi 10.3389/fimmu.2025.1615531
- 2,054 views
- 2 citations
ORIGINAL RESEARCH
Published on 17 Jul 2025
Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER
doi 10.3389/fonc.2025.1621045
- 2,732 views
- 1 citation
ORIGINAL RESEARCH
Published on 26 Jun 2025
Predicting immune-related adverse events in patients with melanoma: the role of interleukin-7 rs16906115 polymorphism and lymphocyte dynamics
doi 10.3389/fimmu.2025.1616325
- 1,937 views
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Other participating journals
Frontiers in Oncology
- 3.3 impact factor
- 6.9 citescore